drugset / Trial / NCT00160628

Open Label Safety and Efficacy Study of Levetiracetam in Korean Patients With Epilepsy

NCT00160628

Phase 3 Completed 100 enrolled UCB Pharma
Non-randomizedSingle-groupOpen-label

Summary

A Korean open-label, community-based trial assessing the efficacy and safety of levetiracetam as adjunctive therapy in partial epilepsy. Similarity with a similar study conducted in Caucasian epileptic subjects will be assessed.

Timeline

Start
2004-03
Primary completion
2004-10
Completion
2004-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Levetiracetam Other / unclassified 3000 mg

Indications